Purixan Approval History
FDA Approved: Yes (First approved April 28, 2014)
Brand name: Purixan
Generic name: mercaptopurine
Dosage form: Oral Suspension
Company: Nova Laboratories, Ltd.
Treatment for: Acute Lymphoblastic Leukemia
Purixan (mercaptopurine) is a nucleoside metabolic inhibitor indicated for the treatment of patients with acute lymphoblastic leukemia.
Development History and FDA Approval Process for Purixan
|Apr 29, 2014||FDA Approves Purixan (mercaptopurine) Oral Suspension|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.